Literature DB >> 21204767

In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotides.

Elisabeth von Guggenberg1, Soraya Shahhosseini, Ingrid Koslowsky, Afsaneh Lavasanifar, David Murray, John Mercer.   

Abstract

The development of antisense oligonucleotides suitable for tumor targeting applications is hindered by low stability and bioavailability of oligonucleotides in vivo and by the absence of efficient and safe vectors for oligonucleotide delivery. Stabilization in vivo has been achieved through chemical modification of oligonucleotides by various means, but effective approaches to enhance their intracellular delivery are lacking. This study reports on the characterization in vitro of a fully phosphorothioated 20-mer oligonucleotide, complementary to p21 mRNA, radiolabeled with fluorine-18 using a thiol reactive prosthetic group. The potential of two novel synthetic block copolymers containing grafted polyamines on their hydrophobic blocks for vector-assisted cell delivery was studied in vitro. Extensive cellular uptake studies were performed in human colon carcinoma cell lines with enhanced or deficient p21 expression to evaluate and compare the uptake mechanism of naked and vectorized radiolabeled formulations. Uptake studies with the two novel biodegradable vectors showed a moderate increase in cell uptake of the radiofluorinated antisense oligonucleotide. The two vectors show, however, promising advantages over conventional lipidic vectors regarding their biocompatibility and subcellular distribution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21204767      PMCID: PMC6283271          DOI: 10.1089/cbr.2010.0813

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  23 in total

Review 1.  Use of positron emission tomography in animal research.

Authors:  S R Cherry; S S Gambhir
Journal:  ILAR J       Date:  2001

Review 2.  Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.

Authors:  Thomas Merdan; Jindrich Kopecek; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

Review 3.  Intracellular trafficking of nonviral vectors.

Authors:  L K Medina-Kauwe; J Xie; S Hamm-Alvarez
Journal:  Gene Ther       Date:  2005-12       Impact factor: 5.250

4.  General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies.

Authors:  B Kühnast; F Dollé; S Terrazzino; B Rousseau; C Loc'h; F Vaufrey; F Hinnen; I Doignon; F Pillon; C David; C Crouzel; B Tavitian
Journal:  Bioconjug Chem       Date:  2000 Sep-Oct       Impact factor: 4.774

5.  Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides.

Authors:  Erik F J de Vries; Joke Vroegh; Philip H Elsinga; Willem Vaalburg
Journal:  Appl Radiat Isot       Date:  2003-04       Impact factor: 1.513

6.  p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis.

Authors:  H Tian; E K Wittmack; T J Jorgensen
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

Review 7.  Cellular delivery of antisense oligonucleotides.

Authors:  I Lebedeva; L Benimetskaya; C A Stein; M Vilenchik
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

8.  In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide.

Authors:  Jingming Bai; Kunihiko Yokoyama; Seigo Kinuya; Kazuhiro Shiba; Ryo Matsushita; Masaaki Nomura; Takatoshi Michigishi; Norihisa Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-21       Impact factor: 9.236

Review 9.  Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives.

Authors:  Cheraz Khélifi Younes; Raphaël Boisgard; Bertrand Tavitian
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

10.  Automated synthesis of an 18F-labelled pyridine-based alkylating agent for high yield oligonucleotide conjugation.

Authors:  Elisabeth von Guggenberg; Jayden A Sader; John S Wilson; Soraya Shahhosseini; Ingrid Koslowsky; Frank Wuest; John R Mercer
Journal:  Appl Radiat Isot       Date:  2009-04-19       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.